Kornimate/medical-research-clean huggingface dataset:
flt3-itd gene mutation and cd135 expression in acute myeloid leukemia.

Conditions: Acute Myeloid Leukemia

Summary: 1. to evaluate expression levels of cd135 2. to assess the frequency of flt3 gene mutations (itd) 3. association between flt3-itd mutation and cd135 expression and their correlation with hematological, immunophenotypic,and biochemical features.

acute leukemias are clonal malignant diseases of immature hematopoietic system ,characterized by clonal evolution and considerable genetic, epigenetic, and phenotypic heterogeneity,and constitute a common cause of morbidity and mortality worldwide.\[1\] gene expression profiling has improved the molecular classification and prognosis of acute leukemias, where molecular testing has become mandatory for further classify into prognostic groups. among the genetic aberrations, alterations of the fms-like tyrosine kinase 3 (flt3) gene. \[2\] flt3 is a type 3 receptor tyrosine kinase that plays an important role in the expansion and proliferation of multi-potent progenitor cells within the bone marrow.\[3\] mutations of flt3 induce a constitutional activation of tyrosine kinases and several downstream targets resulting in proliferation and growth of malignant cells ,myeloproliferative phenotype , high tumor burden,and a characteristic hematological , immunophenotypic and biochemical profile that can be identified during routine diagnostic workup.\[4\]two mutations exist in these cells: flt3-itd (internal tandem duplication), and flt3-tkd, a point mutation in the tyrosine kinase domain.\[5\] flt3-itd is a common driver mutation, seen with a frequency of 20 to 30% ,and significantly affecting the pathogenesis and the clinical outcome . genetic testing for flt3-itd mutation at diagnosis is done to risk stratify patients and to guide therapeutic decisions.\[6-8\] flt3 receptor/cd135 is a transmembrane tyrosine kinase receptor, normally expressed on the surface of hematopoietic stem cells and is lost upon cell differentiation , activation of the receptor resulting in stimulating survival and proliferation, and inhibiting apoptosis of progenitor cells . overexpression of the flt3 receptor has been reported to be associated with high risk for relapse in patients with acute leukemia .\[2\]

Eligibility criteria:
inclusion criteria: * newly diagnosed patients with acute myeloid leukemia (aml), who fullfill the who criteria. exclusion criteria: * aml on top of myeloproliferative neoplasms or mds. * previously diagnosed aml on treatment * patients with any other type of malignant tumors
phase ii pilot study of aminoimidazole carboxamide riboside (aicar), a precursor of purine synthesis, for lesch-nyhan disease

Conditions: Lesch-Nyhan Syndrome

Summary: objectives: i. determine the effects of aminoimidazole carboxamide riboside (aicar) on hematologic manifestations of lesch-nyhan disease. ii. assess the behavioral and neurological benefits of aicar in patients with lesch-nyhan disease. iii. examine the effect of aicar on purine production.

protocol outline: after a 3-day baseline, patients are treated with aminoimidazole carboxamide riboside (aicar) by continuous infusion for 12 days. concurrent allopurinol and folate are allowed.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- men with lesch-nyhan syndrome moderate erythrocyte macrocytosis no active urinary tract disease or impaired renal function

Keywords: lesch-nyhan syndrome inborn errors of metabolism neurologic and psychiatric disorders rare disease
blood pressure reactivity after resistance exercise in older women

Conditions: Resistance Exercise Pressor and Neural Responses in Older Women

Summary: the purpose of this study is to determine and compare the effects of two sessions of resistance exercise in blood pressure reactivity to a mental stress test in older hypertensive women.


Eligibility criteria:
inclusion criteria:older hypertensive women - exclusion criteria:subjects taking hormonal therapy; those with a history of metabolic, neurologic, or cardiovascular diseases other than htn, those with a history of cardiovascular events; subjects with physical limitations; those with non-treated htn; obesity (bmi ≥ 30.0); and subjects taking adrenergic inhibitors or non-dihydropyridinic calcium channel blockers. -

Keywords: resistance training psychological stress aging hypertension autonomic nervous system
esomeprazole for prevention of upper gastrointestinal symptoms associated with continuous use of nsaids

Conditions: GERD

Summary: this study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. the primary variable was to assess the efficacy of esomeprazole 40 mg orally qd (e40) or esomeprazole 20 mg orally qd (e20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper gi symptoms associated with nsaid use, including cox-2 selective nsaids, in patients receiving daily nsaid therapy.


Eligibility criteria:
inclusion criteria: * signed informed consent. * completed the sh-nen-0001 study with relief of upper gi symptom. relief is defined as "last 7 days with a diary assessment of none or minimal, but allowing up to 2 days to be rated as mild during the 7-day period". * a clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily nsaid treatment for at least 6 months. daily nsaid treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include cox-2 selective nsaids, multiple nsaids, and high-dose nsaids. * daily nsaid treatment dose and type: (must have been stable for at least 9 weeks prior to inclusion and; are expected to remain stable for the duration of the study. and; must be administered orally. if more than one type of nsaid treatment is used, at least one type must be administered orally). * hp negative on histology performed at baseline endoscopy in the study shnen- 0001. exclusion criteria: * discontinuation from study sh-nen-0001 * pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation. * pain, discomfort or burning in the upper abdomen not associated with the use of nsaids, including cox-2 selective nsaids. * pregnancy or lactation. women of childbearing potential must maintain effective contraception during the study period as judged by the investigator. * need for continuous concomitant therapy with: (anticoagulants; corticosteroids at doses higher than explained under inclusion criterion)

Keywords: nsaids upper gi symptoms
heart failure therapy and outcomes in patients with heart failure with mildly reduced or preserved ejection fraction

Conditions: Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction

Summary: this was a retrospective observational cohort study using patient data from the get with the guideline-heart failure (gwtg-hf) registry linked to medicare fee-for-service (ffs) claims. the main goal of the study was to compare home-time in medicare ffs patients with heart failure with mildly reduced or preserved ejection fraction discharged with sacubitril/valsartan versus those discharged without sacubitril/valsartan.


Eligibility criteria:
inclusion criteria: * hospitalized for heart failure from 01 january 2016 to 30 september 2021. * were discharged alive (any discharge disposition other than "expired"). * had mildly reduced or preserved ejection fraction (41% to 60%). * had non-missing record of sac/val use at discharge. * continuously enrolled in medicare part a \& b for the 12 months following the index hf hospitalization discharge date or until death. exclusion criteria: * patients who left against medical advice (ama), were transferred to an acute care facility, or discharged to hospice care. * patients who had dialysis as an in-hospital procedure. * patients with a medical history of chronic dialysis. * patients with an in-hospital procedure of heart transplantation. * patients with a medical history of heart transplantation. * patients with an in-hospital procedure of left ventricular assist device. * patients with a medical history of left ventricular assist device.
a study to compare subcutaneous versus intravenous administration of roactemra/actemra (tocilizumab) in participants with moderate to severe active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis. participants were randomized to receive either tocilizumab 162 mg sc weekly plus iv placebo every 4 weeks, or tocilizumab 8 mg/kg iv every 4 weeks plus sc placebo weekly during the double-blind period from baseline to week 24. the double-blind period was followed by a 72-week open-label treatment with some switching of sc and iv administration. no placebo was administered in the open-label phase. participants continued on their stable dose of disease-modifying antirheumatic drugs (dmards) throughout the study. anticipated time on study treatment was 2 years.


Eligibility criteria:
inclusion criteria: * adult participants, ≥ 18 years of age * rheumatoid arthritis of ≥ 6 months duration, according to american college of rheumatology (acr) criteria * swollen joint count (sjc) ≥ 4 (66 joint count), tender joint count (tjc) ≥ 4 (68 joint count) at screening and baseline * inadequate response to current dmard therapy * permitted dmards must be at stable dose for ≥ 8 weeks prior to baseline * oral corticosteroids (≤ 10 mg/day prednisone or equivalent) and nsaids (up to maximum recommended dose) must be at stable dose for ≥ 4 weeks prior to baseline exclusion criteria: * major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization * rheumatic autoimmune disease other than ra * functional class iv (acr classification) * diagnosis of juvenile idiopathic arthritis (jia) or juvenile rheumatoid arthritis (jra) and/or ra before the age of 16 * prior history of or current inflammatory joint disease other than ra * intra-articular or parenteral corticosteroids within 4 weeks prior to baseline * previous treatment with tocilizumab * active current or history of recurrent infection
effectiveness and safety of duloxetine in women experiencing urinary leakage due to physical stress and urge.

Conditions: Urinary Incontinence, Stress

Summary: the purpose of the study is to evaluate the effectiveness of duloxetine in reducing urinary incontinence(leakage of urine)occurrences in women due to physical stress and leakage that occurs during a strong need(urge) to urinate.


Eligibility criteria:
inclusion criteria: * female outpatients greater than or equal to 18 years of age. * experience episodes of urinary incontinence based on diagnostic criteria of at least 4 episodes a week with symptoms for a minimum of three months prior to start of study. * have an educational level and degree of understanding english. * are free of urinary tract infections. * have a discreet episodes of incontinence(i.e. dry between episodes and do not continuously leak.) exclusion criteria: * have received treatment for incontinence within the last 5 years. * suffer from severe constipation. * currently nursing or breast feeding. * any nervous system disease that would affect normal urinary function. * any extension of internal organs beyond the vaginal opening.
a study of the safety and efficacy of ono-7746 in adult cancer patients with chemotherapy induced thrombocytopenia

Conditions: Chemotherapy-Induced Thrombocytopenia

Summary: the primary objective of this study is to evaluate the safety and tolerability of ono-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (cit) scheduled to receive at least two cycles of myelosuppressive chemotherapy on day 1 every 21 days at the same dosages and schedule in the study. the secondary objectives are to characterize the pk profiles of ono-7746 and to explore the pharmacodynamic effect of ono-7746 on cit.


Eligibility criteria:
inclusion criteria: * signed written informed consent * age ≥ 18 years * patients with confirmed solid tumor and scheduled to receive at least two cycles of myelosuppressive chemotherapy on day 1 every 21 days at the same dosage and schedule in the study. * experienced thrombocytopenia as evidenced by a platelet count \< 100 gi/l in the preceding cycle immediately before study enrollment. * ecog performance status ≤ 2 * for females, surgically sterilized, postmenopausal or agree to use an acceptable form of birth control * patients treated with novel anticancer agents (e.g. bevacizumab, erlotinib, trastuzumab, cetuximab) may be allowed if it is considered the standard treatment by the investigator and after consultation and approval from the sponsor * pt/inr and aptt are within 80% to 120% of the normal range exclusion criteria: * experienced thrombocytopenia as evidenced by a platelet count \< 25 gi/l at any time in the preceding cycle immediately before enrollment into the study * history or presence of clinically significant disease * received any tras, or rhuil-11 within the last 4 weeks prior to screening * had received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening). * pregnant, wanting to become pregnant or lactating

Keywords: ono-7746 chemotherapy induced thrombocytopenia thrombocytopenia
continuous local anesthetic infusion following hernia repair

Conditions: Ventral Hernia

Summary: the primary endpoint of this study will determine if subjects receiving a continuous infusion of local anesthetic following laparoscopic ventral hernia repair, with the pain pump installed as described to treat post surgical pain will have a lower incidence of pain than those patients treated with a placebo, saline-filled pain pump.the secondary endpoint of this study will determine if subjects receiving a continuous infusion of local anesthetic following laparoscopic ventral hernia repair, with the pain pump installed as described to treat post surgical pain will have a lower utilization of narcotic analgesic medication than those patients treated with the placebo, saline-filled pain pump.

patients will be screened to determine study eligibility using inclusion/exclusion criteria. following the consent process, subjects will be randomly assigned to a treatment arm (anesthetic or placebo group). baseline data will be collected prior surgical implantation of the pain pump delivery system. both study and control groups will be able to receive supplemental medication for breakthrough pain as determined by the surgeon. post-operative data will be collected up to three weeks following surgery.

Eligibility criteria:
inclusion criteria: \>18 years * asa i,ii,iii * scheduled for laparoscopic ventral hernia repair exclusion criteria: * asa iv or greater * needing emergency surgery * known history of drug abuse * gi, liver, kidney or other condition which, per the surgeon's opinion, could interfere with the absorption, distribution, metabolism or excretion of any drug used during the duration of the study * patients with a prior allergic reaction or dependency to morphine, demerol, dilaudid, fentanyl, marcaine(bupivicaine), lidocaine, or ropivicaine.
heptcell immunotherapy in patients with inactive chronic hepatitis b (chb)

Conditions: Hepatitis B, Chronic

Summary: a study to evaluate the antiviral effects, immunogenicity, and safety of heptcell in treatment-naive patients with inactive chronic hepatitis b (chb) and low hepatitis b surface antigen (hbsag) levels.


Eligibility criteria:
inclusion criteria: * men and women 18 to 65 years of age, inclusive * inactive chb with documented hbsag positivity for at least 12 months before day 1 * qhbsag ≥ 10 iu/ml but ≤ 100 iu/ml in the 12 months prior to screening * hbv dna ≥ 10 iu/ml at screening * ast, alt, inr, albumin, total bilirubin (excluding patients with gilbert syndrome) and direct bilirubin within normal limits at screening exclusion criteria: * positive hepatitis b e antigen (hbeag) at screening * history of a hepatitis b flare or 1-log increase in hbv dna or hbsag in the prior 12 months * undetectable hbv dna at screening * fibroscan \> 8.5 kpa at screening, or history of hepatic fibrosis or cirrhosis (nb, a fibroscan is not required if an examination is performed within 12 months or a liver biopsy was performed within 2 years before screening and no fibrosis \[f1 or greater\] was identified).

Keywords: immunotherapy chb
monitoring antiplatelet drugs in cardiac arrest patients

Conditions: Cardiac Arrest; Myocardial Infarction; Extracorporeal Membrane Oxygenation; Platelet Dysfunction

Summary: dual antiplatelet therapy (dapt) with acetylsalicylic acid (asa) and oral p2y12 inhibitor (clopidogrel, ticagrelor or prasugrel) is recommended in stemi or nstemi patients undergoing primary percutaneous coronary intervention (pci). there is evidence for an increased risk of stent thrombosis after pci despite administration of dapt in patients resuscitated from a cardiac arrest with stemi/nstemi who undergo primary pci, in particular for those treated with hypothermia. point of care aggregometry represents an emerging tool to measure platelet reactivity in patient treated with antiplatelets drugs. among patients with acute coronary syndrome (acs), those requiring veno-arterial extracorporeal membrane oxygenation (va-ecmo) for refractory cardiogenic shock or cardiac arrest represent a growing population burdened by more profound metabolic, pharmacokinetic, hemostatic and physiological alterations due to increased clinical severity and ecmo itself. in addition, profound platelet inhibition can result in a higher risk of bleeding complication, since these patients have to be simultaneously anticoagulated with unfractioned heparin (ufh) and ecmo itself can cause coagulopathy. we aimed to perform an observational prospective cohort study to investigate platelet reactivity in a population of acs patients with different clinical severity.


Eligibility criteria:
inclusion criteria: * patients p2y12 naive * suffering from acute coronary syndrome needing primary percutaneous coronary intervention (pci) and treated with oral antip2y12 drugs exclusion criteria: * known liver or hematological disease * anticoagulant therapy * active bleeding needing blood transfusions.
long-term follow up of viral hepatitis in uremic patients in taiwan

Conditions: Uremia; Viral Hepatitis

Summary: the linkage between viral hepatitis and renal failure is complex. the current study aims to exlore the long-term prevalence of viral hepatitis among uremic patients in taiwan

patients are prospectively recruited from 15 hemodialysis units including one medical center, 3 satellite hospitals and 11 local clinics in taiwan. patients who provided informed consents for blood tests including genetic study related to hcv spontaneous seroclearance are enrolled for analysis. all the eligible subjects are tested for both hcv antibodies (third-generation, enzyme immunoassay; abbott laboratories, north chicago, il) and hepatitis b surface antigen (hbsag). hcv rna is tested by polymerase chain reaction (cobas amplicor hepatitis c virus test, v.2.0; roche diagnostics, branchburg, new jersey, usa; detection limit: 50 iu/ml) twice for at least 6 months apart if anti-hcv is positive to ensure chronicity of hcv infection. hbsag is quantified with the use of a standard quantitative chemiluminescent microparticle immunoassay (architect hbsag, abbott diagnostics). the concentration of hbsag in the specimen is determined using a previously generated architect hbsag calibration curve (range, 0.05-250 iu/ml). samples with serum hbsag titer \>250 iu/ml were diluted at 1:20 and 1:500 with the architect hbsag diluent and retested to expand the upper limit of the dynamic range from 250 to 125,000 iu/ml. serum hbv dna is determined by a standardized automated quantitative pcr assay (cobas amplicor hbv monitor; roche diagnostics; detection limit 200 copies/ml) if patients are seropositive for hbsag.

Eligibility criteria:
inclusion criteria: * uremic patients exclusion criteria: * nil

Keywords: uremia hbv hcv seroclearance
study on the therapeutic effect of tcm treatment for mdr mn

Conditions: Idiopathic Membranous Nephropathy

Summary: to evaluate the effectiveness and safety of the chinese medicine treatment for multiple drug resistance of mn patients with jianpiyiqi and huoxuejiedu recipe.

based on previous research, the investigators hoping to identity the standard treatment program for mdr imn patients with high treatment difficulty, tcm syndrome of s pixushuifan. subsequently, to evaluate the effectiveness and safety of the chinese medicine treatment for multiple drug resistance of mn patients with jianpiyiqi and huoxuejiedu recipe. with twenty national-grade iii hospital of to formed tcm comprehensive treatment plan and to evaluate the effectiveness and safety of the chinese medicine treatment for multiple drug resistance of mn patients with jianpiyiqi and huoxuejiedu recipe. furthermore, search for potential diagnostic predictor in imn by proteomics and metabolomics. the investigators purpose is improve the clinical remission rate of mn, further establish the treatment of tcm in the treatment of mn.

Eligibility criteria:
inclusion criteria: 1. age 18-75 years; 2. gender, nationality; 3. pixushuifan syndrome, imn confirmed by renal biopsy and clinical examination; 4. treatment invalided by two or more than two kinds of hormone or immunosuppressive agents ; 5. ckd phase 1-3（egfr（epi formula）≥30ml/min/1.73m2） exclusion criteria: 1. progressive mn (progressive renal impairment, renal biopsy confirmed necrotic vasculitis and large crescent formation\>50%), combined with iga nephropathy, diabetic nephropathy and other renal diseases; 2. anti-nuclear antibodies, double stranded dna, anca or other indicators of immune disorders; 3. active hepatitis b and liver function test sustained abnormal; 4. patients with malignant tumor or have a history of cancer, hiv infection, history of mental illness, acute central nervous system diseases, severe gastrointestinal diseases; 5. merger with other serious disease and dysfunction of the organ; 6. gravid or lactation woman; 7. other clinical trials are being studied.

Keywords: idiopathic membranous nephropathy jianpiyiqi recipe huoxuejiedu recipe effectiveness safety
a precision medicine approach to target engagement for emotion regulation

Conditions: Emotional Regulation; Depression; Anxiety; Borderline Personality Disorder; Obsessive-Compulsive Disorder; Posttraumatic Stress Disorder; Eating Disorders

Summary: the proposed study is designed to first test whether teaching people personalized or standardized emotion regulation skills leads to greater decreases in daily negative emotion intensity. second, using data from an initial sample, the investigators will prospectively assign an independent sample of participants to receive their predicted optimal or non-optimal skills to determine if it is feasible and efficacious to match participants to the most appropriate training condition. results of these studies may identify the mechanisms by which emotion regulation interventions impact emotional functioning and allow for the development of personalized, evidence-based, and scalable emotion regulation interventions.


Eligibility criteria:
inclusion criteria: * elevated emotion dysregulation exclusion criteria: * lack of proficiency in english * no access to smartphone * conditions requiring greater than outpatient care

Keywords: cognitive-behavior therapy mechanism ecological momentary assessment personalization